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Muscle blind(DM2) is an autosomal dominant multisystemic disorder caused by a CCTG repeat
expansion in intron 1 of the zinc ﬁnger protein 9 (ZNF9) gene.
We present a three ﬁrst-degree relative Italian family (proband, his mother and his sister) with a mild DM2
phenotype associated with a short (CCTG)100 expansion as far as regards the proband and his mother, while
his sister shows larger expansion correlated to a more severe phenotype. FISH analysis with (CAGG)5 probe
demonstrated that nuclear foci of mutant RNA were present in the proband muscle and co-localized with
muscleblind-like proteins, determining their sequestration in the nucleus. This is one of the smallest
expansion reported and the shortest with the evidence of nuclear foci. These data contribute to the clinical
and molecular correlation of ZNF9 gene short expansion.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Myotonic dystrophies (DMs) are autosomal dominant multisyste-
mic diseases that encompass two known genetic subtypes: myotonic
dystrophy type 1 (DM1; OMIM #160900) and type 2 which includes
also as proximalmyotonicmyopathy (DM2/PROMM;OMIM#602668).
Clinical features include myotonia, muscular dystrophy, cardiac
conduction defects, subcapsular cataracts and other systemic features
such as hypogonadism, insulin resistance, and hypogammaglobuline-
mia [1]. However, most of DM2 patients appear to have a more
favorable long-termprognosis as they donot showlate deterioration in
mental status, hypersomnia, dysphagia, gastrointestinal hypermotility,
hearing deﬁcits, ptosis, or other respiratory complications, features
often present in cases of classic DM1. Cardiac arrhythmia is present in a
minority of the patients. The severity of this disease is quite variable.
No congenital case has ever been observed [2,3].
DM2 is caused by a CCTG expansion in intron 1 of ZNF9 gene (3q13.3-
q24, Locus ID#AY329622) [4] coding for zincﬁngerprotein-9 involved in
a CAP-independent translation of cellular transcripts [5]. The pathologicDino Ferrari, Dipartimento di
Fondazione I.R.C.C.S. Ospedale
el.: +39 02 55033843; fax: +39
ari).
l rights reserved.allele consists in an expansion of the complex repeat tract (TG)n(TCTG)n
(CCTG)n that accumulates as ribonuclear inclusions and may alter
activity of RNA-binding proteins such as muscle blind like-proteins
(MBNL). In unaffected individuals the repeat is up to 27 CCTG-long,
whereas inpatients 75-11000CCTGrepeatswere observed [3], andoften
more than one expanded allele can be detected in a single patient. No
signiﬁcant correlation between the age of onset and expansion sizewas
observed. Still debated is the smallest pathogenic size of the expansion.
Here, we describe an Italian family with DM2 clinical, electro-
physiological, and muscle biopsy features associated with a variable
CCTG expansion. Avery short (CCTG)100 expansionwas detected in two
patients, the proband and his mother, determining a pathogenic effect
by nuclear sequestration of MBNL1 (Muscle blind-like protein 1).
2. Patients
2.1. Patient 1(proband)
The proband is a 32 year-oldman presenting with the symptoms of
“stiffness”, myalgia and proximal legweakness. Since his childhood, he
began to notice difﬁculties in initiating his leg movements such as at
the onset of physical exercise or in sprint running. This sensation
would last few seconds, following which he could continue the motor
activity without further difﬁculty. Over the years, this symptom
demonstrated mild progression and did not vary with temperature or
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fatigue. His past medical history was otherwise unremarkable and he
took no medications.
On examination, cognitive function and cranial nerves were intact.
He has moderate frontal balding and no temporal muscle atrophy.
Handgrip myotonia was evident. His examination revealed no facial or
neck ﬂexor and extensor weakness, moderate shoulder girdle
(Medical Research Council, MRC 4) and mild proximal (elbow ﬂexors
and extensors MRC 4) weakness, normal distal arm and hand strength
(MRC 5). Examination of the lower extremities revealed mild pelvic-
girdle (ileopsoas, MRC 4) and moderate distal leg muscle weakness
(MRC 4). No muscle atrophy was noted. The remainder of the
neurological examination was unremarkable.
Serum creatine kinase (CK) levels varied between 210 and 320 U/L
(n.v. 180 U/L). Other blood examinations, including thyroids stimulat-
ing hormone levels, were normal.
Electromyography (EMG) showed widespread myotonic dis-
charges, as well as occasional positive sharp waves in a number of
regions including the right deltoid, supraspinatus, and biceps. In these
muscles, motor unit potentials were mildly reduced in amplitude and
duration, whereas recruitment and ﬁring rate were normal. Nerve
conduction studies were normal.
Brain MRI, split-lamp examination, electrocardiography, echocar-
diography and respiratory function were normal.
2.2. Patient 2
Themother of patient 1 was evaluated at age 58 years. She noted in
her forties muscle fatigue after physical exercise. She complained also
of myalgias. She denied muscle stiffness or other muscle symptoms.
On examination, cognitive function and cranial nerves were intact.
There were no clinical signs of myotonia. The strength of facial, neck
ﬂexor and extensor muscles was normal. Shoulder girdle, elbow
ﬂexors and extensors were moderately weak (MRC 4). Distal arm and
hand strength was normal (MRC 5). Examination of the lower
extremities revealed mild pelvic-girdle weakness (MRC 4) and normal
distal leg strength. No muscle atrophy was noted.
Split-lamp examination, electrocardiography and respiratory func-
tion were normal. Echocardiography showed an ejection fraction of
65%, the other parameters were normal. CK levels were between 224
and 250 U/L. Nerve conduction studies and EMG were normal.
2.3. Patient 3
The older sister of the proband, a 35 year-old woman, showed a
more clinical severe DM2 phenotype compared with her relatives. Her
symptoms started at around the age of 5 years, when she presented
mild leg weakness and myalgia. Later during her childhood she
complained of generalized limb weakness and signiﬁcant muscle
stiffness, usually at the onset of physical activity. At school, she wasFig. 1. Histopatological analysis of patient 1 muscle biopsy. A) Hematoxylin and Eosin stain
scattered angulated atrophic ﬁbers (250×). B) ATPase pH 4.6 evidencing small type II groupunable to practice sports and she noticed the improvement of her
stiffness with activity.
She had no abortions and did not complain about worsening of
symptoms, e.g. stiffness, myotonia or weakness, during the course of
pregnancies or delivery of her two children that were referred as
healthy. Her past medical history was otherwise unremarkable and
she took no medications.
At the neurological examination, she has gripmyotonia,weakness of
the neck ﬂexors (sternocleidomastoideus, MRC 4) moderate shoulder
girdle weakness (MRC 4), and mild proximal and distal arm and hand
weakness (ﬁnger ﬂexors, MRC 4). In the lower limbs, weakness was
symmetrical and mostly proximal, with weak muscles graded as
follows: 4 hip ﬂexors and extensors, 4 hip abductors, 4 knee ﬂexors
and extensors, 5 ankle dorsiﬂexion, all symmetrical. She could not get up
from the ground in a squatting position. She was able to walk unaided,
but had difﬁculty rising from a chair and sitting up from supine.
No muscle atrophy was evident. She had neither signs of mental
retardation nor cognitive impairment. The remainder of the neuro-
logical examination was unremarkable.
No cataract was present. Her electrocardiographic and echocardio-
graphic examinations were normal. Nerve conduction velocities were
normal. EMG showedmyotonic runs in limbmuscles. In the laboratory
examination, complete blood count and blood biochemistry were
normal. CK ranged between 247 and 349 U/l.
3. Methods
3.1. Histopathological studies
After informed consent, a muscle biopsy was taken from the left
biceps from patient 1 at the age of 32 years, according to a protocol
approved by the Institutional Review Board of the “IRCCS Foundation
Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy”.
Muscle tissue was fresh-frozen in liquid nitrogen-cooled isopentane,
sectioned at 8 µm. Cryostatic cross sectionswere processed according to
standard histological/histochemical techniques [6].
3.2. Genetic analysis
Blood sampleswere obtained from the three patients, after informed
consent. In order to preserve the integrity of genomic DNA samples,
extraction from peripheral leukocytes was performed following the
“salting out” protocol. DNA was extracted as well from cryopreserved
muscle biopsy of patient 1. Genetic screening for DM1 (DMPK gene) was
ﬁrst performed and the outcomewas negative. Subsequently, we tested
the patients for DM2. As ﬁrst step, a PCR-based allele sizing across
marker CL3N58, which includes the CCTG repeat stretch of the ZNF9
gene, was made in order to check for normal alleles using primers
previously described [4], so that the wild-type PCR products range from
250 bp to 280 bp. Brieﬂy, the ampliﬁcation was performed in 35 cycles,ing demonstrating variation in ﬁber size, together with pyknotic nuclear clumps and
ing ﬁbers (100×).
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GoTaqDNA Polymerase by Promega (Promega,WI, USA, www.promega.
com). Afterwards, DNA both from blood and frommuscle went through
a XL-PCR to draw out possible expanded alleles. Brieﬂy, 100 and 200 ng
of DNA were ampliﬁed using the same primer pair and TaKaRa LATaq
1.5 U (TAKARA BIO INC., Japan, www.takara-bio.co.jp), with a 10 min
extension step. Ampliﬁed DNAwas run on a 1% agarose gel, blotted onto
a nylon membrane, and hybridized to a 32P-labelled probe.
Ampliﬁcation products were cloned to seize their expansions in
TOPO-TA Cloning system (Invitrogen, Carlsbad, CA, USA, www.
invitrogen.com) and sequenced by Big Dye Terminator Cycle Sequen-
cing Kit in an automated sequencer 3100 (Applied Biosystem, Foster
City, USA, www.appliedbiosystems.com).
3.3. Fluorescent in situ hybridization analysis (FISH) and Muscleblind 1
(MBNL1) immunoﬂuorescence
FISH was performed on frozen muscle sections from patient 1
using a (CAGG)5 probe as previously reported [7].
Following the post-hybridization wash, the immunoﬂuorescence
protocol for MBLN1 was performed as previously described [8], using
a polyclonal rabbit anti-MBNL1 (gift of Prof. C.A. Thornton, University
of Rochester, New York, USA).
The interaction between ribonuclear inclusions and MBNL1
nuclear accumulation was examined by analysis of images obtained
at confocal microscopy.
4. Results
4.1. Histopathological studies
Histology performed on the proband's muscle showed amyopathic
pattern with an increased centrally nucleated myoﬁbers havingFig. 2. Southern blot of XL-PCR showing expanded alleles. A) Family tree including proband
expanded alleles. 100 and 200 ng of DNAwere ampliﬁed for each sample. Lanes 1–2: patient
11: empty; lanes 12–16: negative controls. C) Southern blot of XL-PCR on proband's muscle a
(CCTG)32, whereas the bands comprised between 500 and 600 bp correspond to up (CCTG)pronounced ﬁbre size variability, nuclear clumps and a preferential
atrophy of type 2 ﬁbres. A mild increase of endomysial connective
tissue was present. Necrosis or inﬂammatory inﬁltrate was not
detectable (Fig. 1).
4.2. Genetic analysis
Ampliﬁcation of CL3N58 marker detected a single normal allele of
252 bp, presenting an interrupted expansion of 17 CCTG in the
proband and in patient 3, and 260 bp in patient 2, with a non
continuous (CCTG)19. Southern blot revealed the presence of one band
whose size is comprised between 500 and 600 bp, and corresponds to
an expansion of about 100 CCTG in patients 1 (blood and muscle) and
2 (blood) (Fig. 2).
Analysis by cloning further demonstrated in both patients an
uninterrupted (CCTG)32-repeat pre-expansion. The wide lower spots
present in both proband and patient 2 is likely to include the
preexpansion alleles. Southern blot analysis on patient 3 showed a
large expanded allele of approximately 2.5 kb. Each patient was
proven negative for mutations in CLCN1 gene coding for skeletal
muscle chloride channel, known to possibly worsen the DM2 clinical
phenotype [9].
4.3. FISH analysis
The ribonuclear inclusions formed by pathologic retained
expansions in DM2 can be visualized by ﬂuorescent in situ
hybridization (FISH). Immunoﬂuorescence analysis in human ske-
letal muscle section from patient 1 showed that ribonuclear
inclusions co-localize with MBNL1 foci within muscle nuclei
(Fig. 3). The confocal microscopy images conﬁrmed the co-localiza-
tion between ribonuclear inclusions (red) and MBNL1 foci (green),
both merged (yellow) in nucleus (blue) (Fig. 3). We detected the's mother, I.1; proband, II.1; proband's sister, II.2. B) Southern blot of XL-PCR showing
1 (blood); lanes 3–4: patient 3; lanes 5–6: patient 2; lanes 7–10: positive controls; lane
mpliﬁed DNA. The wide lower spots in patients 1 and 2 include the preexpansion alleles
100 repeats.
Fig. 3. Direct visualization of the DM2 expansions by FISH and immunofuorescence analysis for Musclebind 1 (MBLN1). A–C: immunoﬂuorescence analysis of ribonuclear inclusions and
MBNL1 in human skeletal muscle from patient 1. Ribonuclear inclusions (asterisk, panel A, red spots) colocalize with MBNL1 foci (asterisk, panel B, green spots) within muscle nuclei
(asterisk, panel C, blue, DAPI stained). D–F: confocal images of FISH, using a RNA (CAGG)5 Texas red labelled probe, andMBNL1 IHCwere performed onmuscle sections from patient 1. The
ribonuclear inclusions (panel A, red spot) and MBNL1 foci (panel B, green spot) merge (panel C, yellow spot) in nucleus (panel C, blue). Scale Bar: A–C: 100 µm; D–F: 4 µm.
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rate of colocalization N90%.
5. Discussion
In DM1, there is a direct correlation between expansion size and
clinical severity of the disease, the expansion tends to increase when
transmitted from one generation to the next and pathologic alleles are
referred to ﬁxed ranges of expansion [10].
In DM2, although anticipation has been reported, there is no
obvious evidence for intergenerational expansions. In addition, there
is no clear correlation between the size of the (CCTG)n expansion and
the severity of the clinical phenotype [3]. Furthermore, there is the
need to discriminate pre-mutational alleles from small pathogenic
alleles.
As described by Liquori et al. [11], alleles displaying an unin-
terrupted stretch of 20 CCTG can be valued as premutational. Indeed,
the repeat that was found in patients 1 and 2 by cloning comprised 32
succeeding CCTG without interruption. They showed as well a larger
expansion. As in none of our patients we found the coexistence of
wild-type, premutational and expanded alleles it would have been of
interest to analyze previous generations from this family to check the
stability of the premutational expansion.
Furthermore, we detected an expansion of 100 CCTG in blood of
patient 1 and 2 and in the muscle of patient 1. This is one of the
shortest expansions reported in the literature. It has been previously
mentioned in one large collection of DM2 patient, the detection of a 75
CCTG expansion, but without a detailed clinical report [3].
Our three ﬁrst-degree relatives demonstrated a different combina-
tion of clinical, biochemical and electrophysiological features with
two of them carrying the same CCTG expansion. Clinical features of
the patients described in this study are typical of DM 2 [12–14].
Patient 1, with a short CCTG expansion, presented symptoms of
muscle stiffness beginning in his childhood. He showed chronic
myopathic changes in his muscle biopsy and FISH analysis by (CAGG)5
probe demonstrated that nuclear foci ofmutant RNAwere present in his
muscle and colocalize with MBNL1, further conﬁrming the diagnosis.
Patient1 patternof expansion inmusclewas likehis one inblood (Fig. 2).On the other hand, patient 3 carrying a larger expansion presented
myotonia and weakness since her childhood, with a degree of
disability slightly severe than his brother, likely correlating her
worse phenotype with molecular ﬁndings.
In the muscle biopsy of patient 1 with short expansion, we were
able to detect the presence of nuclear foci and their co-localization
with MBLN1. This is the shortest expansion in which this analysis was
performed. Our ﬁnding establishes the lowest bounds of sensitivity of
the described protocol.
These data suggest that expansion of 100 CCTG are long enough to
be retained in the nuclei. This is in contrast with that observed in DM1
where an incomplete nuclear retention of short repeats from
minimally affected patients is found. In these cases, small (150 CUG)
repeats were associated to nuclear foci, but only in approximately 15%
of nuclei [15].
Current models of DM1 and DM2 suggest a “spliceopathy” as the
primary pathogenic mechanism and, as a consequence, the failure of
the essential switch from an embryonic to adult splicing pattern. This
results in aberrant expression of embryonic isoforms that are unable
to support the functional requirements of adult tissues [16].
The effects of “spliceopathy” on different transcripts may provide a
basis for the multisystemic features of DM1 and DM2.
In conclusion, the ﬁndings conﬁrm the broad spectrum of clinical,
electrophysiological and pathological manifestations of DM2 patients
that can be seen within the same family. These data contribute to the
deﬁnition of the minimal pathogenetic size of CCTG expansion
allowing the recognition and diagnosis of such disease.
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